Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 7, 2012, Pages 627-634

  Sugimoto, M ^a   Shirai, N ^b   Nishino, M ^b   Kodaira, C ^a   Uotani, T ^a   Yamade, M ^a   Sahara, S ^a   Ichikawa, H ^a   Sugimoto, K ^a   Miyajima, H ^a   Furuta, T ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Enshu General Hospital Shizuoka   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; RABEPRAZOLE;

ADULT; ALLELE; ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; EXON; GASTRIC PH MONITORING; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTRIC MUCOSA; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; RABEPRAZOLE; TIME FACTORS; YOUNG ADULT;

EID: 84866242987     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12014     Document Type: Article

References (39)

1. Walsh JH, Peterson WL,. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
2. Furuta T, Sagehashi Y, Shirai N, et al,. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-73.
3. Furuta T, Shirai N, Watanabe F, et al,. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 453-60.
4. Sugimoto M, Furuta T, Shirai N, et al,. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-23.
5. Hixson LJ, Kelley CL, Jones WN, et al,. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med 1992; 152: 726-32.
6. + ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
7. Barer D, Ogilvie A, Henry D, et al,. Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. N Engl J Med 1983; 308: 1571-5.
8. Bell NJ, Burget D, Howden CW, et al,. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
9. Sugimoto M, Nishino M, Kodaira C, et al,. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. Digestion 2011; 85: 9-17.
10. Nasseri-Moghaddam S, Mofid A, Ghotbi MH, et al,. Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther 2008; 28: 144-53.
11. Hatlebakk JG, Katz PO, Castell DO,. Medical therapy. Management of the refractory patient. Gastroenterol Clin North Am 1999; 28: 847-60.
12. Joh T, Miwa H, Higuchi K, et al,. Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol 2007; 42: 444-9.
13. Miwa H, Sasaki M, Furuta T, et al,. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 2007; 26: 69-77.
14. Sugimoto M, Nishino M, Kodaira C, et al,. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 2011; 17: 1858-65.
15. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al,. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
16. Peghini PL, Katz PO, Bracy NA, et al,. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
17. Hatlebakk JG, Katz PO, Kuo B, et al,. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40.
18. Katsube T, Adachi K, Kawamura A, et al,. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000; 14: 1049-56.
19. Ishizaki T, Horai Y,. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 (Suppl. 3): 27-36.
20. Horai Y, Kimura M, Furuie H, et al,. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15: 793-803.
21. Shirai N, Furuta T, Moriyama Y, et al,. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37.
22. Shirai N, Furuta T, Xiao F, et al,. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002; 16: 837-46.
23. Sugimoto M, Furuta T, Shirai N, et al,. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76: 290-301.
24. Chang M, Dahl ML, Tybring G, et al,. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-63.
25. Kubota T, Chiba K, Ishizaki T,. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-6.
26. Furuta T, Ohashi K, Kosuge K, et al,. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-61.
27. Furuta T, Shirai N, Takashima M, et al,. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11: 341-8.
28. Sugimoto M, Furuta T, Shirai N, et al,. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 2005; 77: 302-11.
29. Nishino M, Sugimoto M, Kodaira C, et al,. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 2010; 55: 1627-36.
30. Kurata S, Kanagawa T, Yamada K, et al,. Fluorescent quenching-based quantitative detection of specific DNA/RNA using a BODIPY((R)) FL-labeled probe or primer. Nucleic Acids Res 2001; 29: E34.
31. Torimura M, Kurata S, Yamada K, et al,. Fluorescence-quenching phenomenon by photoinduced electron transfer between a fluorescent dye and a nucleotide base. Anal Sci 2001; 17: 155-60.
32. De Morais SM, Wilkinson GR, Blaisdell J, et al,. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
33. Adachi K, Fujishiro H, Katsube T, et al,. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001; 16: 1191-6.
34. Kawamura M, Ohara S, Koike T, et al,. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-73.
35. Kawamura M, Ohara S, Koike T, et al,. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 2007; 22: 222-6.
36. Yasuda S, Horai Y, Tomono Y, et al,. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-54.
37. Furuta T, Shirai N, Xiao F, et al,. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolisers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70: 484-92.
38. Lou HY, Chang CC, Sheu MT, et al,. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 2009; 65: 55-64.
39. Furuta T, Shirai N, Sugimoto M, et al,. Administration design of proton pump inhibitor based on CYP2C19 genetic polymorphism. DMPK Lecture Note 2005; 20: 8-15.